Moderna, Inc. - Common Stock (NQ:MRNA)

Bargain-hunters should give these stocks a close look.

3 Once-in-a-Decade Buying Opportunities ↗

February 18, 2026

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the...

Topics Artificial Intelligence

Why Moderna (MRNA) Stock Is Trading Up Today

February 18, 2026

So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?

Topics Economy

These S&P500 stocks are moving in today's session ↗

February 18, 2026

Via Chartmill

Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition ↗

February 13, 2026

Via Chartmill

Why Moderna Stock Just Popped ↗

February 18, 2026

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review ↗

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

February 18, 2026

Via Chartmill

February 18, 2026

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

Via Stocktwits

What's going on in today's pre-market session: S&P500 movers ↗

February 18, 2026

Via Chartmill

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

February 18, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

3 Stocks Under $50 with Warning Signs

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Shopify's Whiplash Day ↗

February 17, 2026

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call.

Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

February 17, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

3 Cash-Burning Stocks That Fall Short

February 15, 2026

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2%...

Topics Bankruptcy

MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook

February 14, 2026

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

February 13, 2026

Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...

Via MarketMinute

Topics Earnings

Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Moderna (MRNA) Q4 2025 Earnings Call Transcript

Topics Economy

Top S&P500 movers in Friday's session ↗

February 13, 2026

Via Chartmill

Friday's session: top gainers and losers in the S&P500 index ↗

February 13, 2026

Via Chartmill

Moderna (MRNA) Q4 2025 Earnings Call Transcript ↗

February 13, 2026

Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its GAAP loss of $2.11 per share was 18.9% above...

Topics Earnings

Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations

February 13, 2026

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Topics Artificial Intelligence

February 13, 2026

Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today ↗

February 13, 2026

Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.

Via Stocktwits

Topics Bonds ETFs Economy

Moderna: Stock to Avoid or Bad News Buy? ↗

February 12, 2026

Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.

Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration...

FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%

February 12, 2026

Via MarketMinute

Topics Earnings

The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation

February 12, 2026

The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of...

Via Finterra

Topics Initial Public Offering Intellectual Property

AI Agents and the Jobs Report Jitter: A Wall Street Balancing Act ↗

February 12, 2026

Via Chartmill

Topics Artificial Intelligence

What To Expect From Moderna’s (MRNA) Q4 Earnings

February 11, 2026

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before market hours. Here’s what to look for.